| Public Notice | Monitoring | N/A | N/A | Jul 27, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 3, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 3, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 3, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 3, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 17, 2024 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.022 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.028 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 17, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 17, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 17, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.027 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0269 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0269 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0269 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0269 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 5, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 5, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 24, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |